Tiotropium bromide [Spiriva; Boehringer Ingelheim] and peginterferon- -2b plus ribavirin [Peg-Intron plus Rebetol; Schering-Plough] have been recommended for approval

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1459, 2004-01, pp. : 22-22

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Schering-Plough's peginterferon (PEG IFN)- -2b plus ribavirin [Peg-Intron plus Rebetol] has been granted priority review status in Japan for a new indication

By  

Inpharma, Vol. 1, Iss. 1495, 2005-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

Tiotropium bromide [Spiriva; Boehringer Ingelheim] has received final approval in Japan

By  

Inpharma, Vol. 1, Iss. 1465, 2004-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Peginterferon-α-2b [Pegintron; Schering-Plough] has been approved by the Chinese State Food and Drug Administration for chronic hepatitis B;

By  

Inpharma, Vol. 1, Iss. 1584, 2007-01 ,pp. : 27-27

Adis International

Access to resources Recommend Favorite

The average wholesale price (AWP) at which Pfizer and Boehringer Ingelheim are launching tiotropium bromide [Spiriva] is 30% less than the AWP of GlaxoSmithKline's salmeterol/fluticasone propionate [Advair]

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 454, 2004-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Peginterferon -2a Plus Ribavirin versus Interferon -2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C

By Sullivan S.D.  

PharmacoEconomics, Vol. 22, Iss. 4, 2004-01 ,pp. : 257-265

Adis International

Access to resources Recommend Favorite